Antipsychotic adjunctive therapy to mood stabilizers and 1‐year rehospitalization rates in bipolar disorder: A cohort study. (9th December 2016) - Hochman, Eldar
Abstract : Objectives: Antipsychotic adjunctive therapy to mood stabilizers (MSs) may improve relapse prevention; however, only a few naturalistic studies, reflecting more generalizable bipolar disorder (BD) samples, support this notion. We compared the 1‐year rehospitalization rates of manic patients with bipolar I disorder (BD‐I) who were discharged with MS (lithium or valproate) monotherapy or with adjunctive atypical or typical antipsychotic therapy. Methods: A total of 201 patients with BD‐I who were hospitalized with manic episodes between 2005 and 2013 were retrospectively followed for 1‐year rehospitalization rates according to treatment at discharge: MS monotherapy, MS with atypical antipsychotics, and MS with typical antipsychotics. Additionally, time to rehospitalization during the 1‐year period after discharge was compared between treatment groups. Multivariable survival analyses adjusted for covariates known to influence rehospitalization were conducted. Results: Rehospitalization rates within 1 year were significantly lower in the MS with atypical antipsychotics group (6.3%) compared to the MS monotherapy group (24.3%, P =.008) and to the MS with typical antipsychotics group (20.6%, P =.02). Time to rehospitalization was significantly longer for the MS with atypical antipsychotics group (345.5 days) compared to the MS monotherapy group (315.1 days, P =.006) and to the MS with typical antipsychotics group (334.1 days, P =.02). The MS with atypical antipsychotics group had a significantly reduced adjusted risk of rehospitalization (hazard ratio=0.17, 95% confidence interval: 0.05‐0.61, P =.007) compared to the MS monotherapy group. Conclusions: Atypical antipsychotic adjunctive therapy to MSs may be more effective than MS monotherapy in preventing rehospitalization during the 1‐year period after a BD manic episode.